Multiple sclerosis: disease biomarkers as indicated by pathophysiology.

Area of Science:

• Neuroimmunology
• Neurology
• Biomarker Discovery

Background:

• Multiple sclerosis (MS) is a complex central nervous system inflammatory demyelinating disease.
• MS exhibits significant heterogeneity in genetics, immunopathogenesis, clinical course, and treatment response.
• Accurate patient subtyping is crucial for effective management due to MS heterogeneity.

Purpose of the Study:

• To review the current evidence and potential applications of antibodies as biological markers in MS.
• To explore the role of antibodies in MS diagnosis, classification, and disease activity prediction.
• To highlight the importance of biomarkers for developing personalized therapeutic strategies in MS.

Main Methods:

• Review of existing scientific literature and studies on antibodies in MS.
• Analysis of evidence linking intrathecal antibody production and B-cell dominance to disease progression.
• Synthesis of information on antibodies as diagnostic, prognostic, and predictive tools in MS.

Main Results:

• Intrathecal antibody production and B-cell dominance are associated with more progressive MS.
• Antibodies show potential as biomarkers for MS diagnosis and classification.
• Biomarkers, including antibodies, are key to predicting disease activity and clinical course.

Conclusions:

• Antibodies represent promising biological markers for multiple sclerosis.
• Utilizing antibody biomarkers can facilitate differential diagnosis and patient stratification.
• Biomarker-guided approaches are essential for tailoring MS treatments to individual patient needs and disease subtypes.